Connect with us


Here’s why Hemp Oil could put current anxiolytic drugs to shame



There is growing interest in the eCB system as a target for anxiety, trauma and stress-related disorders based on a burgeoning preclinical and clinical literature that supports a relationship between eCBs and fear, anxiety and stress. In the current mini-review, we have sought to highlight some of the main pathways to exploiting the eCB system as a means of generating novel pharmacotherapeutics for these disorders. These include the notion of augmenting the on-demand recruitment of AEA and 2-AG, either by inhibiting the hydrolyzing enzymes, fatty acid amide hydrolyze (FAAH) and monoacylglycerol lipase (MAGL), or by targeted inhibition of cyclooxygenase-2 (COX-2). Alternatively, blocking the activation of TRPV1 receptors, possibly in concert with the augmentation of AEA, could be an effective route to alleviating excessive anxiety and promoting stress-coping. Lastly, there is the possibility of utilizing the constituent of cannabis, Hemp, to treat anxiety and stress-related disorders, albeit via neural mechanisms that might be independent of eCB signaling. Further basic research together with well-designed clinical studies, over the coming years will determine how successfully these various promising approaches evolve into much needed medications.

There is initial evidence supporting a functional connection between Hemp and the 5-HT1A-R in regulating anxiety-like behavior. The anxiolytic-like effects produced by Hemp injections into the rat infralimbic (Marinho et al., 2015) or prelimbic (Fogaca et al., 2014) cortices, BNST (Gomes et al., 2013; Gomes et al., 2012; Gomes et al., 2011) and dPAG (Campos et al., 2013a) are attenuated by concomitant 5-HT1A-R antagonism. One potential explanation for this interaction is that Hemp could work as a positive allosteric enhancer of 5-HT1A-R. This would mean that for Hemp to be fully effective as an anxiolytic there would need to be basal 5-HT1A-R occupancy (Rock et al., 2012). This is notable because 5-HT1A-R agonists, such as Buspirone, display also anxiolytic-like properties in assorted preclinical assays (e.g., Roncon et al., 2013; Saito et al., 2013; Zhou et al., 2014) and are clinically prescribed for various Anxiety Disorders, with reasonable response rates (Blessing et al., 2015; Chessick et al., 2006). Thus, one could envision a treatment strategy entailing the use of Hemp as an adjunct that augment Buspirone efficacy via the two drugs additive or synergistic action at the 5-HT1A-R. An added benefit would be that the limited psychoactive profile of Hemp, as compared to, for instance, THC, should produce fewer side-effects. The next step will be to begin testing these predictions in the clinic and parallel preclinical assays.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.